Definium Therapeutics (MMQ0) AI Stock Analysis

Company Guidance

The company reiterated near-term clinical and financial guidance: three pivotal DT120 toplines are expected imminently—EMERGE (MDD, enrollment 149) later this quarter with a 6‑week primary endpoint, VOYAGE (GAD, enrollment 214) expected early Q3 and PANORAMA (GAD, >200 enrolled) expected late Q3 with 12‑week primaries—and a planned HAVEN PTSD study in 2027; VOYAGE and PANORAMA are now powered at ≥99% to detect a 5‑point placebo‑adjusted difference (EMERGE was powered at 80% with significance possible at ~3 points), the Phase III program targets durability of a single administration for at least 12 weeks (Part B follows patients up to one year and allows up to four additional open‑label treatments), Phase II showed 12‑week durability at 100 µg, and DT120 holds Breakthrough Therapy designation in GAD; financially Q1 2026 R&D was $41.5M (up $18.1M YoY, $15.2M of which was DT120), G&A $17.7M (up $8.9M YoY), net loss $77.1M (vs $23.3M), a $20.0M mark‑to‑market warrant impact tied to a share price rise from $13.39 to $18.90, cash and investments of $373.4M supporting runway into 2028, market sizing noted ~4.2M U.S. adults with ≥2 prior treatment failures and a 1% TAM capture modeled as ≈$2B annual revenue, operationally aiming for a 5–8 hour patient journey (vs 10–12 in Phase II) with a single in‑person monitor supported by remote backup, and a potential DEA scheduling acceleration that could shave roughly 90 days from post‑approval access.